PMID- 12567910
OWN - NLM
STAT- MEDLINE
DCOM- 20030926
LR  - 20171116
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 35
IP  - 12
DP  - 2000 Dec
TI  - [Neuroprotective effect of alpha-dihydroergocryptine depends on activation of 
      nuclear factor kappa B].
PG  - 898-901
AB  - AIM: To investigate the relationship between the neuroprotective effect of 
      alpha-dihydroergocryptine (alpha-DHEC) and the activation of nuclear factor Kappa 
      B (NF-Kappa B). METHODS: Adult male rats were subjected to cerebral ischemia 
      induced by middle cerebral artery occlusion (MCAO). DNA binding activity of 
      NF-Kappa B was determined with electrophoretic mobility shift assay (EMSA) in 
      animals subjected to varying durations of cerebral ischemia. Neuroapoptosis 
      induced by ischemic damage was measured by deoxynucleotidy transferase-mediated 
      dUTP nick end labeling (TUNEL) assay and flow cytometry (FCM) analysis. RESULTS: 
      No change was observed in nuclear NF-Kappa B DNA binding in normal animal. A low 
      level of constitutive NF-Kappa B DNA binding was detected in animals subjected to 
      cerebral ischemia of 1 h, and significant increase in the amount of active 
      NF-Kappa B in nuclear extracts was observed after cerebral ischemia of 3 h, 6 h, 
      and 12 h. Peak of NF-Kappa B DNA binding was observed at the time point of 3 h. 
      Animals subjected to cerebral ischemia of 3 h potentially initiates 
      neuroapoptosis and activates NF-Kappa B in nuclear extract. Alpha-DHEC (100 
      micrograms.kg-1 and 150 micrograms.kg-1) showed significant protective effect on 
      neuroapoptosis-induced by cerebral ischemia of 3 h, and inhibiting NF-Kappa B 
      activation using 100 mg.kg-1 pyrrolidinedithiocarbamate (PDTC) in the continuous 
      presence of alpha-DHEC, the neuroprotective effect of alpha-DHEC was blocked. 
      CONCLUSION: The findings suggest that the neuroprotetive effect of alpha-DHEC may 
      depend on the activation of NF-Kappa B.
FAU - Zheng, S Q
AU  - Zheng SQ
AD  - Department of Pharmacology, Sun Yat-Sen University of Medical Science, Guangzhou 
      510080, China.
FAU - Li, T
AU  - Li T
FAU - Xuan, Y X
AU  - Xuan YX
FAU - Lin, S Z
AU  - Lin SZ
FAU - Chen, L J
AU  - Chen LJ
FAU - Yan, G M
AU  - Yan GM
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (NF-kappa B)
RN  - 0 (Neuroprotective Agents)
RN  - 67V3FSL2GL (Dihydroergocryptine)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Brain Ischemia/etiology/prevention & control
MH  - Dihydroergocryptine/*pharmacology/therapeutic use
MH  - Infarction, Middle Cerebral Artery/complications
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Neurons/cytology
MH  - Neuroprotective Agents/*pharmacology/therapeutic use
MH  - Random Allocation
MH  - Rats
MH  - Rats, Wistar
EDAT- 2003/02/06 04:00
MHDA- 2003/09/27 05:00
CRDT- 2003/02/06 04:00
PHST- 2003/02/06 04:00 [pubmed]
PHST- 2003/09/27 05:00 [medline]
PHST- 2003/02/06 04:00 [entrez]
PST - ppublish
SO  - Yao Xue Xue Bao. 2000 Dec;35(12):898-901.